Search Results - "Hitre E"

Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial.

Authors: Hitre, E Budai, B Takácsi-Nagy, Z et al.

Source: British Journal of Cancer. 9/3/2013, Vol. 109 Issue 5, p1117-1122. 6p. 1 Diagram, 2 Charts.

Effects of the lactase 13910 C/T and calcium-sensor receptor A986S G/T gene polymorphisms on the incidence and recurrence of colorectal cancer in Hungarian population.

Authors: Bácsi K Hitre E Kósa JP et al.

Source: BMC Cancer. 2008, Vol. 8, p317-317. 1p.

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

Authors: Jerusalem, G. Farah, S. Courtois, A. et al.

Source: Annals of Oncology. Oct2021, Vol. 32 Issue 10, p1256-1266. 11p.

P-086 - EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment.

Authors: Su, M. Chen, L. Hitre, E. et al.

Source: Annals of Oncology. 2019 Supplement, Vol. 30, piv23-iv23. 1p.

604P Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status.

Authors: Brose, M.S. Keam, B. Robinson, B. et al.

Source: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1708-S1709. 2p.

941TiP A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)

Authors: Khalique, S. Oliva, M. Even, C. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS653-S653. 1p.

9P Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study.

Authors: Salazar Soler, R. Santos Vivas, C. Macias, I. et al.

Source: Annals of Oncology. 2024 Supplement 1, Vol. 35, pS6-S6. 1p.

1653P Cabozantinib (C) vs placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes by duration of prior lenvatinib (L) treatment.

Authors: Brose, M.S. Krajewska, J.A. Vaisman, F. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1297-S1298. 2p.

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study.

Authors: Rubovszky, G. Láng, I. Ganofszky, E. et al.

Source: European Journal of Cancer. Dec2013, Vol. 49 Issue 18, p3806-3812. 7p.

P-225 - Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.

Authors: Javle, M. Borbath, I. Clarke, S. et al.

Source: Annals of Oncology. 2019 Supplement, Vol. 30, piv62-iv62. 1p.

323PSubcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis.

Authors: Kümmel, S Tondini, C A Abraham, J et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.

Authors: Brose MS Keam B Krajewska J et al.

Source: Frontiers in oncology [Front Oncol] 2026 Mar 04; Vol. 16, pp. 1748566. Date of Electronic Publication: 2026 Mar 04 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

A randomized, open-label, two-way crossover clinical trial to evaluate the food effect on pharmacokinetics and safety of DHP107 in patients with advanced solid tumors: the FEEL study.

Authors: Hitre E Láng I Páll D

Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2026 May 30; Vol. 96 (1). Date of Electronic Publication: 2026 May 30.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Multicenter Study

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.

Authors: Wainberg ZA Kang YK Lee KW et al.

Source: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2024 May; Vol. 27 (3), pp. 558-570. Date of Electronic Publication: 2024 Feb 03.

Publication Type: Clinical Trial, Phase II; Randomized Controlled Trial; Journal Article

Journal Info: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 100886238 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1436-3305 (Electronic) Linking ISSN: 14363291 NLM ISO Abbreviation: Gastric Cancer Subsets: MEDLINE

Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.

Authors: Capdevila J Krajewska J Hernando J et al.

Source: Thyroid : official journal of the American Thyroid Association [Thyroid] 2024 Mar; Vol. 34 (3), pp. 347-359. Date of Electronic Publication: 2024 Jan 23.

Publication Type: Randomized Controlled Trial; Journal Article

Journal Info: Publisher: Mary Ann Liebert Publishers Country of Publication: United States NLM ID: 9104317 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-9077 (Electronic) Linking ISSN: 10507256 NLM ISO Abbreviation: Thyroid Subsets: MEDLINE

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.

Authors: Babiker HM Picozzi V Chandana SR et al.

Corporate Authors: Babiker HM Picozzi V Chandana SR et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Jul 20; Vol. 43 (21), pp. 2350-2360. Date of Electronic Publication: 2025 May 31.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.

Authors: Biganzoli G Isnaldi E Richard F et al.

Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Jun 03; Vol. 222, pp. 115438. Date of Electronic Publication: 2025 Apr 17.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.

Authors: Brose MS Robinson BG Sherman SI et al.

Source: Cancer [Cancer] 2022 Dec 15; Vol. 128 (24), pp. 4203-4212. Date of Electronic Publication: 2022 Oct 19.

Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

Corrigendum: High Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer.

Authors: Polk N Budai B Hitre E et al.

Source: Pathology oncology research : POR [Pathol Oncol Res] 2022 Oct 06; Vol. 28, pp. 1610658. Date of Electronic Publication: 2022 Oct 06 (Print Publication: 2022).

Publication Type: Published Erratum

Journal Info: Publisher: Frontiers Media S. A Country of Publication: Switzerland NLM ID: 9706087 Publication Model: eCollection Cited Medium: Internet ISSN: 1532-2807 (Electronic) Linking ISSN: 12194956 NLM ISO Abbreviation: Pathol Oncol Res Subsets: MEDLINE; PubMed not MEDLINE

High Neutrophil-To-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) Are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer.

Authors: Polk N Budai B Hitre E et al.

Source: Pathology oncology research : POR [Pathol Oncol Res] 2022 Apr 27; Vol. 28, pp. 1610315. Date of Electronic Publication: 2022 Apr 27 (Print Publication: 2022).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Media S. A Country of Publication: Switzerland NLM ID: 9706087 Publication Model: eCollection Cited Medium: Internet ISSN: 1532-2807 (Electronic) Linking ISSN: 12194956 NLM ISO Abbreviation: Pathol Oncol Res Subsets: MEDLINE